Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study;Kosteneffektivität von atorvastatin bei der behandlung des akuten koronarsyndroms in Deutschland anhand der MIRACL-studie

Medizinische Klinik

Volumn 99, Issue 9, 2004, Pages 500-505

  Lange, Alex P ^c   Szucs, Thomas D ^a,b  

^a Basel   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c NONE

Author keywords

Acute coronary syndrome; Atorvastatin; Cost effectiveness; MIRACL

Indexed keywords

ATORVASTATIN; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; GERMANY; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; VALIDATION PROCESS;

EID: 4644271819     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-004-1076-8     Document Type: Article

References (20)

1. Weltgesundheitsorganisation-WHO (http://www.who. int/whr/2002/annex/en, abgerufen 7. 12. 2003).
2. Statistisches Bundesamt Deutschland-Destatis (http://www.destatis.de/ basis/d/gesu/gesutab19.htm, abgerufen 7. 12. 2003).
3. Gesundheitsberichterstattung des Bundes - Gesundheitsbericht für Deutschland 1998 (http://www. gbe-bund.de, abgerufen 7. 12. 2003).
4. Schwartz GG, Oliver MF, Ezekowitz MD, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578-81.
5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. JAMA 2001;285:1711-8.
6. Buller N, Gillen D, Casciano R, et al. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom. Pharmacoeconomics 2003;21;Suppl 1:25-32.
7. Institut für das Entgeltsystem im Krankenhaus (InEK gGmbH). 2. Projekthericht (http://www.g-drg.de/optionsmodell/GDRG_Projektbericht_Band_2. zip, abgerufen 7. 12. 2003).
8. Editio Cantor. Rote Liste online (http://www.roteliste.de, abgerufen 7. 12. 2003).
9. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
11. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
12. Schwartz GG, Ganz P, Waters D, et al. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol 2003;92:1109-12.
13. Smith DG, McBurney CR. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Pharmacoeconomics 2003;21: Suppl 1:13-23.
14. Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001;8:9-16.
15. Hilleman DE, Heineman SM, Foral PA. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 2001;20:819-22.
16. Caro J, Klittich W, McGuire A, et al. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997;315:1577-82.
17. Caro J, Klittich W, McGuire A, Ford I, et al. West of Scotland Coronary Prevention Study: international economic analysis of primary prevention of cardiovascular disease with pravastatin inWOSCOPS. Eur Heart J 1999;20:263-8.
18. Grover SA, Coupal L, Paquet S, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
19. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. Curr Med Res Opin 2002;18:220-8.
20. Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention - can we save lives and money with statins? Arch Intern Med 2003;163:333-9.